Increased sales of its Quadramet and Prostascint radiopharmaceuticals led Princeton, NJ-based biopharmaceutical firm Cytogen to higher revenues in the first quarter of 2007 (end-March 31).
Revenues were $4.8 million, compared with $4.4 million in the first quarter of 2006. Cytogen also reported a net loss of $4.8 million, compared with a net loss of $7.7 million in the same quarter a year ago.
Product revenues were comprised of sales of radiopharmaceuticals Quadramet (samarium Sm-153 lexidronam injection) and Prostascint (capromab pendetide). First-quarter results do not include revenues from Caphosol and Soltamox (tamoxifen citrate), which were introduced in March 2007 and August 2006, respectively.
By AuntMinnie.com staff writers
May 11, 2007
Related Reading
Advanced Magnetics, Cytogen settle suit, February 16, 2007
Cytogen begins phase III study for Quadramet, July 26, 2007
Advanced Magnetics to defend Cytogen suit, January 30, 2006
Cytogen sues Advanced Magnetics, January 26, 2006
Higher 2005 revenues for Cytogen, January 9, 2006
Copyright © 2007 AuntMinnie.com
